HIV AIDS opportunistic infections: Difference between revisions

Jump to navigation Jump to search
m (Bot: Removing from Primary care)
 
(44 intermediate revisions by 7 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{AIDS}}
{{AIDS}}
{{CMG}}; {{AE}} {{AL}}
{{CMG}}; {{AE}} {{AL}}; {{JH}}


==Overview==
==Overview==
Before the widespread use of potent combination antiretroviral therapy (ART), opportunistic infections (OIs), which have been defined as infections that are more frequent or more severe because of immunosuppression in HIV-infected persons, were the principal cause of morbidity and mortality in this population. In the early 1990s, the use of chemoprophylaxis, immunization, and better strategies for managing acute OIs contributed to improved quality of life and improved survival.<ref name="pmid16741877">{{cite journal |author=Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, Weinstein MC, Freedberg KA |title=The survival benefits of AIDS treatment in the United States |journal=J. Infect. Dis. |volume=194 |issue=1 |pages=11–9 |year=2006 |month=July |pmid=16741877 |doi=10.1086/505147 |url=http://www.jid.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=16741877 |accessdate=2012-04-05}}</ref>  However, the widespread use of ART starting in the mid-1990s has had the most profound influence on reducing OI-related mortality in HIV-infected persons in those countries in which these therapies are accessible and affordable.
It is important to recognize that the relationship between opportunistic infections (OIs) and HIV infection is bi-directional. HIV causes the immunosuppression that allows opportunistic pathogens to cause disease in HIV-infected persons. OIs, as well as other co-infections that may be common in HIV-infected persons, such as sexually transmitted infections (STIs), can adversely affect the natural history of HIV infection by causing reversible increases in circulating viral load that could accelerate HIV progression and increase transmission of HIV. The widespread use of ART starting in the mid-1990s has had the most profound influence on reducing OI-related mortality in HIV-infected persons in those countries in which these therapies are accessible and affordable. Major OIs characteristic of AIDS include viral infections such as [[CMV retinitis]], mucosal [[HSV]], and [[varicella zoster]], bacterial infections such as [[bacillary angiomatosis]], [[tuberculosis]], [[mycobacterium avium complex]], and [[syphilis]], and fungal infections such as [[cryptococcosis]], mucocutaneous [[candidiasis]], [[coccidiomycosis]], and [[pneumocystis jirovecii]] pneumonia.


==HIV Opportunistic Infections==
==Opportunistic Infections==
===Bacteria===
===Bacteria===
{| style="border: 0px; font-size: 85%; margin: 3px; width:950px;" align=center
{| style="border: 0px; font-size: 85%; margin: 3px; width:1000px;" align=center
|valign=top|
|valign=top|
|+
|+
! style="background: #4479BA; color:#FFF;  width: 100px;" | Disease
! style="background: #4479BA; color:#FFF;  width: 100px;" | Disease
! style="background: #4479BA; color:#FFF;  width: 200px;" | Description
! style="background: #4479BA; color:#FFF;  width: 200px;" | Description
! style="background: #4479BA; color:#FFF;  width: 200px;" | Clinical Findings
! style="background: #4479BA; color:#FFF;  width: 250px;" | Clinical Findings
! style="background: #4479BA; color:#FFF;  width: 200px;" | Diagnosis  
! style="background: #4479BA; color:#FFF;  width: 200px;" | Diagnosis  
! style="background: #4479BA; color:#FFF;  width: 200px;" | Prevention / Prophylaxis
! style="background: #4479BA; color:#FFF;  width: 200px;" | Prevention / Prophylaxis
Line 20: Line 20:
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | [[Mycobacterium avium complex]] (MAC)
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | [[Mycobacterium avium complex]] (MAC)
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*M.avium is the etiologic agent in 95% of patients with MAC disease
*''[[M. avium]]'' is the etiologic agent in 95% of patients with MAC disease
*The greatest risk of disease occurs among patients with a CD4+ <50 cells/µL
*The greatest risk of disease occurs among patients with a [[CD4]]+ <50 cells/µL
| style="padding: 5px 5px; background: #F5F5F5;" | [[Fever]], night sweats, weight loss, [[fatigue]], [[diarrhea]], and [[abdominal pain]].
| style="padding: 5px 5px; background: #F5F5F5;" | [[Fever]], night sweats, weight loss, [[fatigue]], [[diarrhea]], and [[abdominal pain]].


| style="padding: 5px 5px; background: #F5F5F5;" |  Isolation of MAC from cultures of blood, lymph node or bone marrow.
| style="padding: 5px 5px; background: #F5F5F5;" |  Isolation of MAC from cultures of blood, lymph node or bone marrow.
| style="padding: 5px 5px; background: #F5F5F5;" | Prophylaxis is indicated when CD4 < 50 cells/µL  
| style="padding: 5px 5px; background: #F5F5F5;" | Prophylaxis is indicated when [[CD4]] < 50 cells/µL  
*Azithromycin 1200 mg PO once weekly, OR  
*[[Azithromycin]] 1200 mg PO once weekly, OR  
*Clarithromycin 500 mg PO BID
*[[Clarithromycin]] 500 mg PO BID
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Clarithromycin 500 mg PO twice daily + ethambutol 15 mg/kg PO daily , OR  
*[[Clarithromycin]] 500 mg PO twice daily + [[ethambutol]] 15 mg/kg PO daily , OR  
*Azithromycin 500–600 mg + ethambutol 15 mg/kg PO daily
*[[Azithromycin]] 500–600 mg + [[ethambutol]] 15 mg/kg PO daily
:<small>(Testing of susceptibility to clarithromycin or azithromycin is recommended)</small>
:<small>(Testing of susceptibility to [[clarithromycin]] or [[azithromycin]] is recommended)</small>
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | Respiratory Disease  
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | Respiratory Disease  
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Atypical bacterial pathogens such as [[Legionella pneumophila]], [[Mycoplasma pneumoniae]], and [[Chlamydophila]] species have been reported as infrequent causes of community-acquired bacterial pneumonia in HIV-infected individuals
*The frequency of [[Pseudomonas aeruginosa]] and [[Staphylococcus aureus]] as community-acquired pathogens is higher in HIV-infected individuals
| style="padding: 5px 5px; background: #F5F5F5;" | [[Fever]], [[chills]], rigors, [[chest pain]] or [[pleurisy]], productive [[cough]], and [[dyspnea]]
| style="padding: 5px 5px; background: #F5F5F5;" | Diagnosis is the same as in HIV-negative patients ([[chest X-ray]], [[sputum]] analysis)
| style="padding: 5px 5px; background: #F5F5F5;" | Pneumococcal and influenza [[vaccination]] is recommended for all HIV patients. <br> <small>Note: Live attenuated influenza vaccine is contraindicated in HIV-infected persons </small>
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Treatment should be pathogen specific.
| style="padding: 5px 5px; background: #F5F5F5;" |
*Empiric therapy:
| style="padding: 5px 5px; background: #F5F5F5;" |
:*[[Amoxicillin/clavulanate]] + [[azithromycin]] or [[clarithromycin]], OR
:*[[Levofloxacin]] 750 mg PO once daily
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | Enteric Infections
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | Enteric Infections
Line 44: Line 50:
*The most common routinely cultured enteric bacteria among HIV-infected adults in the United States are [[Salmonella]], [[Shigella]], and [[Campylobacter]].
*The most common routinely cultured enteric bacteria among HIV-infected adults in the United States are [[Salmonella]], [[Shigella]], and [[Campylobacter]].
*Other pathogens include [[E. coli]] and [[C. difficile]].
*Other pathogens include [[E. coli]] and [[C. difficile]].
| style="padding: 5px 5px; background: #F5F5F5;" | Severe and prolonged diarrheal disease, potentially associated with fever, bloody diarrhea, and weight loss.
| style="padding: 5px 5px; background: #F5F5F5;" | Severe and prolonged [[diarrheal]] disease, potentially associated with fever, bloody diarrhea, and weight loss.
| style="padding: 5px 5px; background: #F5F5F5;" |  
| style="padding: 5px 5px; background: #F5F5F5;" |  
*The diagnosis of Gram-negative bacterial enteric infection is established through cultures of stool and blood.  
*The diagnosis of Gram-negative bacterial enteric infection is established through cultures of stool and blood.  
*Stool sample for C. difficile toxin or polymerase chain reaction assay (if recent antibiotic use)
*Stool sample for [[C. difficile]] toxin or [[polymerase chain reaction]] assay (if recent antibiotic use)
| style="padding: 5px 5px; background: #F5F5F5;" |Antimicrobial prophylaxis to prevent bacterial enteric illness usually is not recommended.
| style="padding: 5px 5px; background: #F5F5F5;" |Antimicrobial prophylaxis to prevent bacterial enteric illness usually is not recommended.
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Treatment should be pathogen specific.
*Treatment should be pathogen specific.
*Empiric therapy: Ciprofloxacin  500–750 mg PO q12h
*Empiric therapy: [[Ciprofloxacin]] 500–750 mg PO q12h
* Oral or IV hydration therapy as appropriate.
* Oral or IV hydration therapy as appropriate.
|-
|-
Line 66: Line 72:
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | [[Syphilis]]
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | [[Syphilis]]
| style="padding: 5px 5px; background: #F5F5F5;" | Treponema pallidum is the causative pathogen.  
| style="padding: 5px 5px; background: #F5F5F5;" |  
| style="padding: 5px 5px; background: #F5F5F5;" | Single painless nodule  
*Treponema pallidum is the causative pathogen.
*Early syphilis in HIV-infected patients may cause a transient decrease in CD4 count and increase in HIV viral load.
| style="padding: 5px 5px; background: #F5F5F5;" |
*Primary: Single painless nodule that ulcerates (chancre) or multiple atypical chancres may be seen.
*Secondary: More rapid progression or severity in HIV patients.  Manifestations include maculopapular skin lesions, condyloma lata, lymphadenopathy, fever, malaise, anorexia, arthralgias, and headache. 
*Terciary:  Manifestations of neurosyphilis, such as concomitant uveitis and meningitis, may be more common in HIV-infected persons.  Other manifestations include cardiovascular syphilis and gummatous syphilis.
| style="padding: 5px 5px; background: #F5F5F5;" |  
| style="padding: 5px 5px; background: #F5F5F5;" |  
*Serologic tests: VDRL, RPR, FTA-ABS, TP-PA
*Serologic tests: VDRL, RPR, FTA-ABS, TP-PA
*Darkfield microscopy and tests to detect T. pallidum in lesion exudates or tissue (biopsy with silver stain) are definitive for diagnosing early syphilis
*Darkfield microscopy and tests to detect T. pallidum in lesion exudates or tissue (biopsy with silver stain) are definitive for diagnosing early syphilis
| style="padding: 5px 5px; background: #F5F5F5;" |
*Routine serologic screening for syphilis is recommended at least annually for all HIV- infected patients who are sexually active.
*Prophylaxis is indicated in patients who were exposed sexually within 90 days preceding the diagnosis of primary, secondary, or early-latent syphilis in a sex partner or exposed >90 days before syphilis diagnosis in a sex partner, if serologic test results are not available immediately and the opportunity for follow-up is uncertain.
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Primary: Benzathine penicillin G 2.4 million units IM for 1 dose
|-
*Secondary and terciary: Benzathine penicillin G 2.4 million units IM weekly for 3 doses
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | 
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | 
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" colspan=5| Table adapted from Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents<ref name="Guidelines"> {{cite web| title=Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the
| style="padding: 5px 5px; background: #F5F5F5;" colspan=6| Table adapted from Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents<ref name="Guidelines"> {{cite web| title=Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the
prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.  Accessed Oct 2014| url=http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf }} </ref>
prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.  Accessed Oct 2014| url=http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf }} </ref>
|}
|}


===Virus===
===Virus===
{| style="border: 0px; font-size: 85%; margin: 3px; width:950px;" align=center
{| style="border: 0px; font-size: 85%; margin: 3px; width:1000px;" align=center
|valign=top|
|valign=top|
|+
|+
! style="background: #4479BA; color:#FFF;  width: 100px;" | Disease
! style="background: #4479BA; color:#FFF;  width: 100px;" | Disease
! style="background: #4479BA; color:#FFF;  width: 200px;" | Description
! style="background: #4479BA; color:#FFF;  width: 200px;" | Description
! style="background: #4479BA; color:#FFF;  width: 200px;" | Clinical Findings
! style="background: #4479BA; color:#FFF;  width: 250px;" | Clinical Findings
! style="background: #4479BA; color:#FFF;  width: 200px;" | Diagnosis  
! style="background: #4479BA; color:#FFF;  width: 200px;" | Diagnosis  
! style="background: #4479BA; color:#FFF;  width: 200px;" | Prevention / Prophylaxis
! style="background: #4479BA; color:#FFF;  width: 200px;" | Prevention / Prophylaxis
! style="background: #4479BA; color:#FFF;  width: 200px;" | Treatment
! style="background: #4479BA; color:#FFF;  width: 200px;" | Treatment
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | [[Cytomegalovirus]] Disease
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | [[Cytomegalovirus]] Infection
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*The greatest risk of disease occurs among patients with a CD4+ <50 cells/µL
*The greatest risk of disease occurs among patients with a CD4+ <50 cells/µL
Line 119: Line 120:
*For sight threatening lesions: Add intravitreal injections of ganciclovir or foscarnet to normal regimen.
*For sight threatening lesions: Add intravitreal injections of ganciclovir or foscarnet to normal regimen.
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | [[Herpes Simplex Virus]] Disease
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | [[Herpes Simplex Virus]] Infection
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Approximately 70% of HIV-infected persons are HSV-2 seropositive and 95% are seropositive for either HSV-1 or HSV-2.
*The greatest risk of disease occurs among patients with a CD4+ <100 cells/µL
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*HSV-1: Orolabial herpes (cold sores, fever blisters).
*HSV-2: Genital herpes (papules, vesicles or ulcers).
*Non-mucosal HSV infections, such as HSV keratitis, HSV encephalitis, HSV hepatitis, and herpetic whitlow, are similar in presentation to manifestations observed in HIV-seronegative individuals
| style="padding: 5px 5px; background: #F5F5F5;" |Viral culture, HSV DNA PCR, and HSV antigen detection are available methods for diagnosis of mucocutaneous lesions.
| style="padding: 5px 5px; background: #F5F5F5;" |Prophylaxis with antiviral drugs to prevent primary HSV infection is not recommended.
| style="padding: 5px 5px; background: #F5F5F5;" |
<u>Genital lesions</u> (for 5-14 days): 
*Valacyclovir 1 g PO BID, or
*Famciclovir 500 mg PO BID, or
*Acyclovir 400 mg PO TID
<u>Oral lesions</u> (for 5-10 days): 
*Valacyclovir 1 g PO BID, or
*Famciclovir 500 mg PO BID, or
*Acyclovir 400 mg PO TID
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | [[Varicella-Zoster Virus]] Diseases
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | [[Varicella-Zoster Virus]] (VZV) Infection
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*The greatest risk of herpes zoster occurs among patients with a CD4+ <200 cells/µL
*Because most HIV-infected adults in the United States are VZV seropositive, primary varicella is an uncommon.
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Varicella rash tends to have a central distribution with lesions first appearing on the head, then trunk, and finally the extremities, evolving through stages of macules, papules, vesicles, pustules, and crusts
*Herpes zoster manifests as a painful cutaneous eruption in a dermatomal distribution, often preceded by prodromal pain.
| style="padding: 5px 5px; background: #F5F5F5;" |
*Diagnosis is made clinically.
*History of varicella or VZV exposure, a rash that began with a dermatomal pattern, and VZV serologic testing to assess prior VZV infection may be helpful.
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Avoid exposure to individuals with varicella or herpes zoster.
*Prophylaxis with antiviral drugs to prevent varicella is not recommended.
*Varicella vaccination is recommended for patients with CD4 > 200 cells/µL.
*Post-exposure prophylaxis: VariZIG 125 IU/10 kg IM
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Valacyclovir 1000 mg PO TID, OR
*Famciclovir 500 mg PO TID
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | Human Herpesvirus-8 Disease
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | Human Herpesvirus-8 Infection
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*The greatest risk of herpes zoster occurs among patients with a CD4+ <200 cells/µL
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Most patients are asymptomatic
*Kaposi Sarcoma:  nontender, purplish, indurated skin lesions.
*Multicentric Castleman’s disease: generalized adenopathy and fever and can progress to multi-organ failure.
*Primary effusion lymphoma characteristically presents with effusions of the pleural, pericardial, or abdominal spaces
| style="padding: 5px 5px; background: #F5F5F5;" |Diagnosis is made with cytologic and immunologic cell markers
| style="padding: 5px 5px; background: #F5F5F5;" |Screening is not recommended
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Kaposi Sarcoma: Start or adjust ART
*Multicentric Castleman’s disease: Valganciclovir 900 mg PO BID for 3 weeks, or Ganciclovir 5 mg/kg IV q12h for 3 weeks, or Valganciclovir 900 mg PO BID + zidovudine 600 mg PO q6h for 7–21 days.
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | [[Human Papillomavirus]] Disease
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | [[Human Papillomavirus]] Infection
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | [[JC Virus]] Infection
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*HPV 16 and 18 are associated with cervical malignancy.
*HPV 6 and 11 cause 90% of genital warts.
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Oral, genital, and anal warts (condyloma acuminata) are usually flat, papular, or pedunculated growths on the mucosa or epithelium.
*Cervical cancer can be asymptomatic or may manifest with bleeding, pain, or a palpable mass.
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Diagnosis of genital and oral warts is made by visual inspection and can be confirmed by biopsy.
*Cytology (Pap test) and colposcopic techniques with biopsy are used to detect CIN.
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*HPV vaccination is recommended in HIV infected patients
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Podophyllotoxin or Imiquimod self-application to warts.
*Cryotherapy, surgical excision, laser surgery.
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" colspan=6| Table adapted from Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents <ref name="Guidelines"> {{cite web| title=Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the
| style="padding: 5px 5px; background: #F5F5F5;" colspan=6| Table adapted from Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents <ref name="Guidelines"> {{cite web| title=Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the
Line 159: Line 196:


===Fungus===
===Fungus===
{| style="border: 0px; font-size: 85%; margin: 3px; width:950px;" align=center
{| style="border: 0px; font-size: 85%; margin: 3px; width:1000px;" align=center
|valign=top|
|valign=top|
|+
|+
! style="background: #4479BA; color:#FFF;  width: 100px;" | Disease
! style="background: #4479BA; color:#FFF;  width: 100px;" | Disease
! style="background: #4479BA; color:#FFF;  width: 200px;" | Description
! style="background: #4479BA; color:#FFF;  width: 200px;" | Description
! style="background: #4479BA; color:#FFF;  width: 200px;" | Clinical Findings
! style="background: #4479BA; color:#FFF;  width: 250px;" | Clinical Findings
! style="background: #4479BA; color:#FFF;  width: 200px;" | Diagnosis  
! style="background: #4479BA; color:#FFF;  width: 200px;" | Diagnosis  
! style="background: #4479BA; color:#FFF;  width: 200px;" | Prevention / Prophylaxis
! style="background: #4479BA; color:#FFF;  width: 200px;" | Prevention / Prophylaxis
Line 175: Line 212:
*Incidence among HIV patients: 2-3 cases per 100 person-year
*Incidence among HIV patients: 2-3 cases per 100 person-year
| style="padding: 5px 5px; background: #F5F5F5;" |Subacute onset of progressive [[dyspnea]], [[fever]], nonproductive [[cough]], and chest discomfort that worsens within days to weeks. [[Tachypnea]], [[tachycardia]], and diffuse dry rales are found in the physical examination.   
| style="padding: 5px 5px; background: #F5F5F5;" |Subacute onset of progressive [[dyspnea]], [[fever]], nonproductive [[cough]], and chest discomfort that worsens within days to weeks. [[Tachypnea]], [[tachycardia]], and diffuse dry rales are found in the physical examination.   
| style="padding: 5px 5px; background: #F5F5F5;" | Clinical presentation, blood tests, or chest x-rays are not pathognomonic for PCP. <br>  [[BAL]] or induced sputum samples are required for a definite diagnosis.
| style="padding: 5px 5px; background: #F5F5F5;" |  
*Clinical presentation, blood tests, or chest x-rays are not pathognomonic for PCP. <br>  [[BAL]] or induced sputum samples are required for a definite diagnosis.
| style="padding: 5px 5px; background: #F5F5F5;" | Start [[TMP-SMX]] prophylaxis when [[CD4]]+ <200 cells/µL or history of oropharyngeal [[candidiasis]].  <br> Discontinue prophylaxis when  CD4+ is >200 cells/µL for >3 month.
| style="padding: 5px 5px; background: #F5F5F5;" | Start [[TMP-SMX]] prophylaxis when [[CD4]]+ <200 cells/µL or history of oropharyngeal [[candidiasis]].  <br> Discontinue prophylaxis when  CD4+ is >200 cells/µL for >3 month.
| style="padding: 5px 5px; background: #F5F5F5;" |  
| style="padding: 5px 5px; background: #F5F5F5;" |  
Line 182: Line 220:
*In patients not on ART, ART should be initiated, when possible, within 2 weeks of diagnosis of PCP  
*In patients not on ART, ART should be initiated, when possible, within 2 weeks of diagnosis of PCP  
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |  Mucocutaneous Candidiasis  
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |  [[Candidiasis|Mucocutaneous Candidiasis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*''Candida albicans'' is the causative agent.
*Oropharyngeal and esophageal candidiasis are common in HIV-infected patients
*The greatest risk of disease occurs among patients with a [[CD4]]+ <200 cells/µL
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Oropharyngeal:  Painless, creamy white, plaque-like lesions that can occur on the buccal surface, hard or soft palate, oropharyngeal mucosa, or tongue surface.
*Esophageal: retrosternal burning pain or discomfort along with [[odynophagia]].
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Usually diagnosed clinically based on the characteristic appearance of lesions (can be scraped off)
*Definitive diagnosis of esophageal candidiasis requires direct endoscopic visualization of lesions with histopathologic demonstration of characteristic Candida yeast
| style="padding: 5px 5px; background: #F5F5F5;" |Routine primary prophylaxis is not recommended
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
<u>Oropharyngeal</u>: 
*[[Fluconazole]] 100 mg PO once daily
<u>Esophageal</u>: 
*[[Fluconazole]] 100 mg (up to 400 mg) PO or IV daily, OR<br>
*[[Itraconazole]] oral solution 200 mg PO daily
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |  Cryptococcosis
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |  [[Cryptococcosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*''Cryptococcus neoformans'' is the causative pathogen.
*The greatest risk of disease occurs among patients with a [[CD4]]+ <100 cells/µL
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Subacute meningitis or meningoencephalitis with fever, malaise, and headache.
*Other symptoms such as lethargy, altered mental status, personality changes, and memory loss may be present.
| style="padding: 5px 5px; background: #F5F5F5;" |
*CSF analysis shows mildly elevated levels of protein, low-to-normal glucose, and pleocytosis consisting mostly of lymphocytes
* Opening pressure in the CSF may be elevated
* Diagnosed through culture of blood or CSF, CSF microscopy with India ink staining, or cryptococcal antigen (CrAg) detection
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Primary prophylaxis or screening for serum CrAg in asymptomatic patients is not recommended in the US
*Prophylactic fluconazole or itraconazole can reduce the frequency of primary cryptococcal disease in patients who have CD4 cell counts <100 cells/mm according to prospective RCT.
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
<u>Induction Therapy</u>:
*Liposomal amphotericin B 3–4 mg/kg IV daily + flucytosine 25 mg/kg PO QID
<u>Consolidation Therapy</u>:
*Fluconazole 400 mg PO or IV once daily
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |  Histoplasmosis
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |  [[Histoplasmosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*''Histoplasma capsulatum'' is the causative pathogen.
*The greatest risk of disease occurs among patients with a [[CD4]]+ <150 cells/µL
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
Fever, fatigue, weight loss, hepatosplenomegaly, cough, chest pain, and dyspnea.
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Detection of Histoplasma antigen in blood, urine or [[BAL]] is a sensitive method for rapid diagnosis of disseminated histoplasmosis and acute pulmonary histoplasmosis.
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Avoid activities known to be associated with increased risk (areas contaminated of bird or bat droppings)
*Start prophylaxis with [[Itraconazole]] 200 mg PO once daily when [[CD4]]+ <150 cells/µL and the patients is at high risk of exposure.
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
<u>Induction Therapy</u>: 
*Liposomal amphotericin B 3 mg/kg IV daily (for 2 weeks)
<u>Consolidation Therapy</u>:
*Itraconazole 200 mg PO TID for 3 days, then BID for > 12 months
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |  Coccidioidomycosis
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |  [[Coccidioidomycosis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Caused by a soil-dwelling fungus that consists of two species, ''Coccidioides immitis'' and ''Coccidioides posadasii''.
*The greatest risk of disease occurs among patients with a [[CD4]]+ <250 cells/µL
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
Focal pneumonia (most common in patients with [[CD4]] >250 cells/µL), diffuse [[pneumonia]], cutaneous disease, [[meningitis]], liver or lymph node involvement.
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Diagnosis is confirmed by culture.
*Serology (IgM and IgG) is useful
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Avoid activities involving exposure to infection while living in or visiting areas in which Coccidioides spp. are endemic.
*Chemoprophylaxis is not recommended.
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
<u>Mild infections</u>:
*Fluconazole 400 mg PO once daily (BII), OR
*Itraconazole 200 mg PO twice daily
<u>Severe infection</u>
*Amphotericin B deoxycholate 0.7–1.0 mg/kg IV daily, OR
*Lipid formulation amphotericin B 4–6 mg/kg IV daily
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |  Aspergillosis
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |  Aspergillosis
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Aspergillus fumigatus is the most common causative agent.
*The greatest risk of disease occurs among patients with a [[CD4]]+ <100 cells/µL
| style="padding: 5px 5px; background: #F5F5F5;" | Symptoms of pneumonia include [[fever]], [[cough]], [[dyspnea]], chest pain, [[hemoptysis]], and hypoxemia
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Lung CT: Halo of low attenuation surrounding a pulmonary nodule or a cavity.
| style="padding: 5px 5px; background: #F5F5F5;" |
* Bronchoscopic examination demonstrates ulcerative or plaque-like lesions adherent to the tracheal wall
| style="padding: 5px 5px; background: #F5F5F5;" |
* Isolation of Aspergillus spp. from respiratory secretions or the finding of septate hyphae consistent with Aspergillus spp. in respiratory samples in association with typical CT findings
| style="padding: 5px 5px; background: #F5F5F5;" | Antifungal therapy is not recommended for prevention.
| style="padding: 5px 5px; background: #F5F5F5;" | [[Voriconazole]] 6 mg/kg IV q12h for 1 day, then 4 mg/kg IV q12h , followed by [[voriconazole]] PO 200 mg q12h after clinical improvement.
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" colspan=6| Table adapted from Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents <ref name="Guidelines"> {{cite web| title=Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the
| style="padding: 5px 5px; background: #F5F5F5;" colspan=6| Table adapted from Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents <ref name="Guidelines"> {{cite web| title=Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the
Line 222: Line 314:


===Parasite===
===Parasite===
{| style="border: 0px; font-size: 85%; margin: 3px; width:950px;" align=center
{| style="border: 0px; font-size: 85%; margin: 3px; width:1000px;" align=center
|valign=top|
|valign=top|
|+
|+
! style="background: #4479BA; color:#FFF;  width: 100px;" | Disease
! style="background: #4479BA; color:#FFF;  width: 100px;" | Disease
! style="background: #4479BA; color:#FFF;  width: 200px;" | Description
! style="background: #4479BA; color:#FFF;  width: 200px;" | Description
! style="background: #4479BA; color:#FFF;  width: 200px;" | Clinical Findings
! style="background: #4479BA; color:#FFF;  width: 250px;" | Clinical Findings
! style="background: #4479BA; color:#FFF;  width: 200px;" | Diagnosis  
! style="background: #4479BA; color:#FFF;  width: 200px;" | Diagnosis  
! style="background: #4479BA; color:#FFF;  width: 200px;" | Prevention / Prophylaxis
! style="background: #4479BA; color:#FFF;  width: 200px;" | Prevention / Prophylaxis
Line 294: Line 386:
prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.  Accessed Oct 2014| url=http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf }} </ref>
prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.  Accessed Oct 2014| url=http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf }} </ref>
|}
|}
==Gallery==
<gallery>
Image:Oral Candidiasis.jpg|'''Oral Candidiasis''' <br> <small> Image obtained from U.S. Department of Veterans Affairs - Image Library [http://www.hiv.va.gov/provider/image-library] (Pediatric AIDS Pictoral Atlas, Baylor International Pediatric AIDS Initiative) </small>
Image:Candida esophagitis.jpg|'''Candida esophagitis''' <br> <small> Image obtained from U.S. Department of Veterans Affairs - Image Library [http://www.hiv.va.gov/provider/image-library] (Paul A. Volberding, MD, University of California San Francisco) </small>
Image:CMV Retinitis.jpg|'''CMV Retinitis''' <br> <small> Image obtained from U.S. Department of Veterans Affairs - Image Library [http://www.hiv.va.gov/provider/image-library] (Paul A. Volberding, MD, University of California San Francisco) </small>
Image:CMV Colitis.jpg|'''CMV Colitis''' <br> <small> Image obtained from U.S. Department of Veterans Affairs - Image Library [http://www.hiv.va.gov/provider/image-library] (Paul A. Volberding, MD, University of California San Francisco) </small>
Image:Herpes simplex.jpg|'''Oral Herpes Simplex''' <br> <small> Image obtained from U.S. Department of Veterans Affairs - Image Library [http://www.hiv.va.gov/provider/image-library] (Arthur Ammann, MD, Global Strategies for HIV Prevention) </small>
Image:Genital herpes simplex.jpg|'''Genital Herpes Simplex''' <br> <small> Image obtained from U.S. Department of Veterans Affairs - Image Library [http://www.hiv.va.gov/provider/image-library] (Paul A. Volberding, MD, University of California San Francisco) </small>
Image: Condyloma acuminatum anogenital warts.jpg|'''Condyloma Acuminatum: Anogenital Warts  ''' <br> <small> Image obtained from U.S. Department of Veterans Affairs - Image Library [http://www.hiv.va.gov/provider/image-library] (Paul A. Volberding, MD, University of California San Francisco) </small>
Image: HPV cutaneous warts.jpg|'''HPV Cutaneous Warts ''' <br> <small> Image obtained from U.S. Department of Veterans Affairs - Image Library [http://www.hiv.va.gov/provider/image-library] (Pediatric AIDS Pictoral Atlas, Baylor International Pediatric AIDS Initiative) </small>
Image: Kaposi Sarcoma HHV-8.jpg|'''Kaposi Sarcoma/ HHV-8''' <br> <small> Image obtained from U.S. Department of Veterans Affairs - Image Library [http://www.hiv.va.gov/provider/image-library] (Paul A. Volberding, MD, University of California San Francisco) </small>
Image:Kaposi sarcoma angiomatous nodule.jpg|'''Kaposi Sarcoma: Angiomatous Nodule ''' <br> <small> Image obtained from U.S. Department of Veterans Affairs - Image Library [http://www.hiv.va.gov/provider/image-library] (Toby A. Maurer, MD, Timothy G. Berger, MD, University of California San Francis ) </small>
Image:PCP X-ray.jpg|'''Pneumocystis jiroveci Pneumonia <br> X-ray shows bilateral, diffuse granular opacities''' <br> <small> Image obtained from U.S. Department of Veterans Affairs - Image Library [http://www.hiv.va.gov/provider/image-library] (Laurence Huang, MD, University of California San Francisco) </small>
Image:Herpes zoster HIV.jpg|''' Herpes Zoster''' <br> <small> Image obtained from U.S. Department of Veterans Affairs - Image Library [http://www.hiv.va.gov/provider/image-library] (Paul A. Volberding, MD, University of California San Francisco) </small>
Image:Herpes zoster - HIV.jpg|'''Herpes Zoster''' <br> <small> Image obtained from U.S. Department of Veterans Affairs - Image Library [http://www.hiv.va.gov/provider/image-library] (Susanne Theresia Duerr, MD; University of Regensburg, Germany; provided courtesy of the Hôpital de Shyria, Rwanda) </small>
Image:Toxoplasma gondii retinal lesions.jpg|'''Toxoplasma gondii Retinal Lesions  ''' <br> <small> Image obtained from U.S. Department of Veterans Affairs - Image Library [http://www.hiv.va.gov/provider/image-library] (Paul A. Volberding, MD, University of California San Francisco) </small>
Image:Toxoplasma gondii CT scan showing cerebral abscess.jpg|'''Toxoplasma gondii: CT scan showing cerebral abscess''' <br> <small> Image obtained from U.S. Department of Veterans Affairs - Image Library [http://www.hiv.va.gov/provider/image-library] (Paul A. Volberding, MD, University of California San Francisco) </small>
Image:Bacillary Angiomatosis HIV.jpg|'''Bacillary Angiomatosis''' <br> <small> Image obtained from U.S. Department of Veterans Affairs - Image Library [http://www.hiv.va.gov/provider/image-library] (Paul A. Volberding, MD, University of California San Francisco) </small>
Image:Bacillary Angiomatosis HIV 2.jpg|'''Bacillary Angiomatosis''' <br> <small> Image obtained from U.S. Department of Veterans Affairs - Image Library [http://www.hiv.va.gov/provider/image-library] (Paul A. Volberding, MD, University of California San Francisco) </small>
Image: HIV_opportunistic01.jpeg| '''Chlamydia psittaci'''. <SMALL><SMALL>''[http://phil.cdc.gov/phil/home.asp From Public Health Image Library (PHIL).] ''<ref name=PHIL> {{Cite web | title = Public Health Image Library (PHIL) | url = http://phil.cdc.gov/phil/home.asp}}</ref></SMALL></SMALL>
Image: HIV_opportunistic02.jpeg| '''Candidemia (Bloodstream infection with Candida)'''. <SMALL><SMALL>''[http://phil.cdc.gov/phil/home.asp From Public Health Image Library (PHIL).] ''<ref name=PHIL> {{Cite web | title = Public Health Image Library (PHIL) | url = http://phil.cdc.gov/phil/home.asp}}</ref></SMALL></SMALL>
Image: HIV_opportunistic04.jpeg| '''Candidiasis in kidney tissue'''. <SMALL><SMALL>''[http://phil.cdc.gov/phil/home.asp From Public Health Image Library (PHIL).] ''<ref name=PHIL> {{Cite web | title = Public Health Image Library (PHIL) | url = http://phil.cdc.gov/phil/home.asp}}</ref></SMALL></SMALL>
Image: HIV_opportunistic05.jpeg| '''Candidiasis in kidney tissue'''. <SMALL><SMALL>''[http://phil.cdc.gov/phil/home.asp From Public Health Image Library (PHIL).] ''<ref name=PHIL> {{Cite web | title = Public Health Image Library (PHIL) | url = http://phil.cdc.gov/phil/home.asp}}</ref></SMALL></SMALL>
Image: HIV_opportunistic06.jpeg| '''Kaposi’s sarcoma due to human herpesvirus 8 (HHV8)'''. <SMALL><SMALL>''[http://phil.cdc.gov/phil/home.asp From Public Health Image Library (PHIL).] ''<ref name=PHIL> {{Cite web | title = Public Health Image Library (PHIL) | url = http://phil.cdc.gov/phil/home.asp}}</ref></SMALL></SMALL>
Image: HIV_opportunistic07.jpeg| '''Penicillium marneffei yeast cells in human spleen'''. <SMALL><SMALL>''[http://phil.cdc.gov/phil/home.asp From Public Health Image Library (PHIL).] ''<ref name=PHIL> {{Cite web | title = Public Health Image Library (PHIL) | url = http://phil.cdc.gov/phil/home.asp}}</ref></SMALL></SMALL>
Image: HIV_opportunistic08.jpeg| '''Gram-positive Mycobacterium tuberculosis bacteria'''. <SMALL><SMALL>''[http://phil.cdc.gov/phil/home.asp From Public Health Image Library (PHIL).] ''<ref name=PHIL> {{Cite web | title = Public Health Image Library (PHIL) | url = http://phil.cdc.gov/phil/home.asp}}</ref></SMALL></SMALL>
Image: HIV_opportunistic09.jpeg| '''Gram-positive Mycobacterium tuberculosis bacteria'''. <SMALL><SMALL>''[http://phil.cdc.gov/phil/home.asp From Public Health Image Library (PHIL).] ''<ref name=PHIL> {{Cite web | title = Public Health Image Library (PHIL) | url = http://phil.cdc.gov/phil/home.asp}}</ref></SMALL></SMALL>
Image: HIV_opportunistic10.jpeg| '''Streptococcus anginosus bacteria'''. <SMALL><SMALL>''[http://phil.cdc.gov/phil/home.asp From Public Health Image Library (PHIL).] ''<ref name=PHIL> {{Cite web | title = Public Health Image Library (PHIL) | url = http://phil.cdc.gov/phil/home.asp}}</ref></SMALL></SMALL>
Image: HIV_opportunistic11.jpeg| '''Intraoral Kaposi’s sarcoma with candidiasis infection'''. <SMALL><SMALL>''[http://phil.cdc.gov/phil/home.asp From Public Health Image Library (PHIL).] ''<ref name=PHIL> {{Cite web | title = Public Health Image Library (PHIL) | url = http://phil.cdc.gov/phil/home.asp}}</ref></SMALL></SMALL>
Image: HIV_opportunistic12.jpeg| '''Oral pseudomembraneous candidiasis infection'''. <SMALL><SMALL>''[http://phil.cdc.gov/phil/home.asp From Public Health Image Library (PHIL).] ''<ref name=PHIL> {{Cite web | title = Public Health Image Library (PHIL) | url = http://phil.cdc.gov/phil/home.asp}}</ref></SMALL></SMALL>
</gallery>


==References==
==References==
{{reflist|2}}
{{reflist|2}}
[[Category:HIV/AIDS]]
[[Category:Disease]]
[[Category:Immune system disorders]]
[[Category:Viral diseases]]
[[Category:Pandemics]]
[[Category:Sexually transmitted infections]]
[[Category:Virology]]
[[Category:Immunodeficiency]]
[[Category:Microbiology]]
[[Category:Emergency mdicine]]
[[Category:Up-To-Date]]
[[Category:Infectious disease]]

Latest revision as of 22:12, 29 July 2020

Sexually transmitted diseases Main Page

AIDS Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating AIDS from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

HIV Opportunistic Infections

HIV Coinfections

HIV and Pregnancy

HIV Infection in Infants

Diagnosis

Diagnostic Study of Choice

AIDS Case Definition

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Nutrition
Drug Resistance

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

HIV Vaccine

Case Studies

Case #1

HIV AIDS opportunistic infections On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of HIV AIDS opportunistic infections

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on HIV AIDS opportunistic infections

CDC on HIV AIDS opportunistic infections

HIV AIDS opportunistic infections in the news

Blogs on HIV AIDS opportunistic infections

Directions to Hospitals Treating AIDS

Risk calculators and risk factors for HIV AIDS opportunistic infections

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [18]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [19]; Jesus Rosario Hernandez, M.D. [20]

Overview

It is important to recognize that the relationship between opportunistic infections (OIs) and HIV infection is bi-directional. HIV causes the immunosuppression that allows opportunistic pathogens to cause disease in HIV-infected persons. OIs, as well as other co-infections that may be common in HIV-infected persons, such as sexually transmitted infections (STIs), can adversely affect the natural history of HIV infection by causing reversible increases in circulating viral load that could accelerate HIV progression and increase transmission of HIV. The widespread use of ART starting in the mid-1990s has had the most profound influence on reducing OI-related mortality in HIV-infected persons in those countries in which these therapies are accessible and affordable. Major OIs characteristic of AIDS include viral infections such as CMV retinitis, mucosal HSV, and varicella zoster, bacterial infections such as bacillary angiomatosis, tuberculosis, mycobacterium avium complex, and syphilis, and fungal infections such as cryptococcosis, mucocutaneous candidiasis, coccidiomycosis, and pneumocystis jirovecii pneumonia.

Opportunistic Infections

Bacteria

Disease Description Clinical Findings Diagnosis Prevention / Prophylaxis Treatment
Mycobacterium avium complex (MAC)
  • M. avium is the etiologic agent in 95% of patients with MAC disease
  • The greatest risk of disease occurs among patients with a CD4+ <50 cells/µL
Fever, night sweats, weight loss, fatigue, diarrhea, and abdominal pain. Isolation of MAC from cultures of blood, lymph node or bone marrow. Prophylaxis is indicated when CD4 < 50 cells/µL
(Testing of susceptibility to clarithromycin or azithromycin is recommended)
Respiratory Disease Fever, chills, rigors, chest pain or pleurisy, productive cough, and dyspnea Diagnosis is the same as in HIV-negative patients (chest X-ray, sputum analysis) Pneumococcal and influenza vaccination is recommended for all HIV patients.
Note: Live attenuated influenza vaccine is contraindicated in HIV-infected persons
  • Treatment should be pathogen specific.
  • Empiric therapy:
Enteric Infections Severe and prolonged diarrheal disease, potentially associated with fever, bloody diarrhea, and weight loss.
  • The diagnosis of Gram-negative bacterial enteric infection is established through cultures of stool and blood.
  • Stool sample for C. difficile toxin or polymerase chain reaction assay (if recent antibiotic use)
Antimicrobial prophylaxis to prevent bacterial enteric illness usually is not recommended.
  • Treatment should be pathogen specific.
  • Empiric therapy: Ciprofloxacin 500–750 mg PO q12h
  • Oral or IV hydration therapy as appropriate.
Bacillary Angiomatosis
  • B. henselae and B. quintana infections have been identified in HIV- infected patients
  • The greatest risk of disease occurs among patients with a CD4+ <50 cells/µL
Cutaneous lesions (red, globular and non-blanching, with a vascular appearance), sub-cutaneous nodules. Histopathologic examination of biopsied tissue Primary chemoprophylaxis for Bartonella-associated disease is not recommended
  • Doxycycline 100 mg PO or IV q12h, OR
  • Erythromycin 500 mg PO or IV q6h
Syphilis
  • Treponema pallidum is the causative pathogen.
  • Early syphilis in HIV-infected patients may cause a transient decrease in CD4 count and increase in HIV viral load.
  • Primary: Single painless nodule that ulcerates (chancre) or multiple atypical chancres may be seen.
  • Secondary: More rapid progression or severity in HIV patients. Manifestations include maculopapular skin lesions, condyloma lata, lymphadenopathy, fever, malaise, anorexia, arthralgias, and headache.
  • Terciary: Manifestations of neurosyphilis, such as concomitant uveitis and meningitis, may be more common in HIV-infected persons. Other manifestations include cardiovascular syphilis and gummatous syphilis.
  • Serologic tests: VDRL, RPR, FTA-ABS, TP-PA
  • Darkfield microscopy and tests to detect T. pallidum in lesion exudates or tissue (biopsy with silver stain) are definitive for diagnosing early syphilis
  • Routine serologic screening for syphilis is recommended at least annually for all HIV- infected patients who are sexually active.
  • Prophylaxis is indicated in patients who were exposed sexually within 90 days preceding the diagnosis of primary, secondary, or early-latent syphilis in a sex partner or exposed >90 days before syphilis diagnosis in a sex partner, if serologic test results are not available immediately and the opportunity for follow-up is uncertain.
  • Primary: Benzathine penicillin G 2.4 million units IM for 1 dose
  • Secondary and terciary: Benzathine penicillin G 2.4 million units IM weekly for 3 doses
Table adapted from Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents[1]

Virus

Disease Description Clinical Findings Diagnosis Prevention / Prophylaxis Treatment
Cytomegalovirus Infection
  • The greatest risk of disease occurs among patients with a CD4+ <50 cells/µL
  • Retinitis is the most common clinical manifestation of CMV end-organ disease
  • Colitis occurs in 5% to 10% of patients with AIDS and CMV end-organ disease, clinical manifestations include weight loss, anorexia, abdominal pain, diarrhea, and malaise.
  • Esophagitis occurs in a small percentage of patients
CMV viremia can be detected by PCR, antigen assays, or culture
  • CMV end-organ disease is best prevented by using ART to maintain CD4 count >100 cells/uL
  • Ganciclovir or valganciclovir primary prophylaxis is not recommended.
  • Some specialists recommend yearly funduscopic examination in patients with CD4 < 50 cells/uL
  • Preferred Regimen: Valganciclovir 900 mg PO daily
  • For sight threatening lesions: Add intravitreal injections of ganciclovir or foscarnet to normal regimen.
Herpes Simplex Virus Infection
  • Approximately 70% of HIV-infected persons are HSV-2 seropositive and 95% are seropositive for either HSV-1 or HSV-2.
  • The greatest risk of disease occurs among patients with a CD4+ <100 cells/µL
  • HSV-1: Orolabial herpes (cold sores, fever blisters).
  • HSV-2: Genital herpes (papules, vesicles or ulcers).
  • Non-mucosal HSV infections, such as HSV keratitis, HSV encephalitis, HSV hepatitis, and herpetic whitlow, are similar in presentation to manifestations observed in HIV-seronegative individuals
Viral culture, HSV DNA PCR, and HSV antigen detection are available methods for diagnosis of mucocutaneous lesions. Prophylaxis with antiviral drugs to prevent primary HSV infection is not recommended.

Genital lesions (for 5-14 days):

  • Valacyclovir 1 g PO BID, or
  • Famciclovir 500 mg PO BID, or
  • Acyclovir 400 mg PO TID

Oral lesions (for 5-10 days):

  • Valacyclovir 1 g PO BID, or
  • Famciclovir 500 mg PO BID, or
  • Acyclovir 400 mg PO TID
Varicella-Zoster Virus (VZV) Infection
  • The greatest risk of herpes zoster occurs among patients with a CD4+ <200 cells/µL
  • Because most HIV-infected adults in the United States are VZV seropositive, primary varicella is an uncommon.
  • Varicella rash tends to have a central distribution with lesions first appearing on the head, then trunk, and finally the extremities, evolving through stages of macules, papules, vesicles, pustules, and crusts
  • Herpes zoster manifests as a painful cutaneous eruption in a dermatomal distribution, often preceded by prodromal pain.
  • Diagnosis is made clinically.
  • History of varicella or VZV exposure, a rash that began with a dermatomal pattern, and VZV serologic testing to assess prior VZV infection may be helpful.
  • Avoid exposure to individuals with varicella or herpes zoster.
  • Prophylaxis with antiviral drugs to prevent varicella is not recommended.
  • Varicella vaccination is recommended for patients with CD4 > 200 cells/µL.
  • Post-exposure prophylaxis: VariZIG 125 IU/10 kg IM
  • Valacyclovir 1000 mg PO TID, OR
  • Famciclovir 500 mg PO TID
Human Herpesvirus-8 Infection
  • The greatest risk of herpes zoster occurs among patients with a CD4+ <200 cells/µL
  • Most patients are asymptomatic
  • Kaposi Sarcoma: nontender, purplish, indurated skin lesions.
  • Multicentric Castleman’s disease: generalized adenopathy and fever and can progress to multi-organ failure.
  • Primary effusion lymphoma characteristically presents with effusions of the pleural, pericardial, or abdominal spaces
Diagnosis is made with cytologic and immunologic cell markers Screening is not recommended
  • Kaposi Sarcoma: Start or adjust ART
  • Multicentric Castleman’s disease: Valganciclovir 900 mg PO BID for 3 weeks, or Ganciclovir 5 mg/kg IV q12h for 3 weeks, or Valganciclovir 900 mg PO BID + zidovudine 600 mg PO q6h for 7–21 days.
Human Papillomavirus Infection
  • HPV 16 and 18 are associated with cervical malignancy.
  • HPV 6 and 11 cause 90% of genital warts.
  • Oral, genital, and anal warts (condyloma acuminata) are usually flat, papular, or pedunculated growths on the mucosa or epithelium.
  • Cervical cancer can be asymptomatic or may manifest with bleeding, pain, or a palpable mass.
  • Diagnosis of genital and oral warts is made by visual inspection and can be confirmed by biopsy.
  • Cytology (Pap test) and colposcopic techniques with biopsy are used to detect CIN.
  • HPV vaccination is recommended in HIV infected patients
  • Podophyllotoxin or Imiquimod self-application to warts.
  • Cryotherapy, surgical excision, laser surgery.
Table adapted from Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents [1]

Fungus

Disease Description Clinical Findings Diagnosis Prevention / Prophylaxis Treatment
Pneumocystis Pneumonia

(Click here for more information)
  • Caused by the fungus Pneumocystis jirovecii.
  • 90% of cases occurred among patients with CD4+ <200
  • Incidence among HIV patients: 2-3 cases per 100 person-year
Subacute onset of progressive dyspnea, fever, nonproductive cough, and chest discomfort that worsens within days to weeks. Tachypnea, tachycardia, and diffuse dry rales are found in the physical examination.
  • Clinical presentation, blood tests, or chest x-rays are not pathognomonic for PCP.
    BAL or induced sputum samples are required for a definite diagnosis.
Start TMP-SMX prophylaxis when CD4+ <200 cells/µL or history of oropharyngeal candidiasis.
Discontinue prophylaxis when CD4+ is >200 cells/µL for >3 month.
  • TMP-SMX
  • Administer adjunctive corticosteroids in patients with pO2 <70 mm Hg or arterial-alveolar O2 gradient >35 mm Hg
  • In patients not on ART, ART should be initiated, when possible, within 2 weeks of diagnosis of PCP
Mucocutaneous Candidiasis
  • Candida albicans is the causative agent.
  • Oropharyngeal and esophageal candidiasis are common in HIV-infected patients
  • The greatest risk of disease occurs among patients with a CD4+ <200 cells/µL
  • Oropharyngeal: Painless, creamy white, plaque-like lesions that can occur on the buccal surface, hard or soft palate, oropharyngeal mucosa, or tongue surface.
  • Esophageal: retrosternal burning pain or discomfort along with odynophagia.
  • Usually diagnosed clinically based on the characteristic appearance of lesions (can be scraped off)
  • Definitive diagnosis of esophageal candidiasis requires direct endoscopic visualization of lesions with histopathologic demonstration of characteristic Candida yeast
Routine primary prophylaxis is not recommended

Oropharyngeal:

Esophageal:

Cryptococcosis
  • Cryptococcus neoformans is the causative pathogen.
  • The greatest risk of disease occurs among patients with a CD4+ <100 cells/µL
  • Subacute meningitis or meningoencephalitis with fever, malaise, and headache.
  • Other symptoms such as lethargy, altered mental status, personality changes, and memory loss may be present.
  • CSF analysis shows mildly elevated levels of protein, low-to-normal glucose, and pleocytosis consisting mostly of lymphocytes
  • Opening pressure in the CSF may be elevated
  • Diagnosed through culture of blood or CSF, CSF microscopy with India ink staining, or cryptococcal antigen (CrAg) detection
  • Primary prophylaxis or screening for serum CrAg in asymptomatic patients is not recommended in the US
  • Prophylactic fluconazole or itraconazole can reduce the frequency of primary cryptococcal disease in patients who have CD4 cell counts <100 cells/mm according to prospective RCT.

Induction Therapy:

  • Liposomal amphotericin B 3–4 mg/kg IV daily + flucytosine 25 mg/kg PO QID

Consolidation Therapy:

  • Fluconazole 400 mg PO or IV once daily
Histoplasmosis
  • Histoplasma capsulatum is the causative pathogen.
  • The greatest risk of disease occurs among patients with a CD4+ <150 cells/µL

Fever, fatigue, weight loss, hepatosplenomegaly, cough, chest pain, and dyspnea.

  • Detection of Histoplasma antigen in blood, urine or BAL is a sensitive method for rapid diagnosis of disseminated histoplasmosis and acute pulmonary histoplasmosis.
  • Avoid activities known to be associated with increased risk (areas contaminated of bird or bat droppings)
  • Start prophylaxis with Itraconazole 200 mg PO once daily when CD4+ <150 cells/µL and the patients is at high risk of exposure.

Induction Therapy:

  • Liposomal amphotericin B 3 mg/kg IV daily (for 2 weeks)

Consolidation Therapy:

  • Itraconazole 200 mg PO TID for 3 days, then BID for > 12 months
Coccidioidomycosis
  • Caused by a soil-dwelling fungus that consists of two species, Coccidioides immitis and Coccidioides posadasii.
  • The greatest risk of disease occurs among patients with a CD4+ <250 cells/µL

Focal pneumonia (most common in patients with CD4 >250 cells/µL), diffuse pneumonia, cutaneous disease, meningitis, liver or lymph node involvement.

  • Diagnosis is confirmed by culture.
  • Serology (IgM and IgG) is useful
  • Avoid activities involving exposure to infection while living in or visiting areas in which Coccidioides spp. are endemic.
  • Chemoprophylaxis is not recommended.

Mild infections:

  • Fluconazole 400 mg PO once daily (BII), OR
  • Itraconazole 200 mg PO twice daily

Severe infection

  • Amphotericin B deoxycholate 0.7–1.0 mg/kg IV daily, OR
  • Lipid formulation amphotericin B 4–6 mg/kg IV daily
Aspergillosis
  • Aspergillus fumigatus is the most common causative agent.
  • The greatest risk of disease occurs among patients with a CD4+ <100 cells/µL
Symptoms of pneumonia include fever, cough, dyspnea, chest pain, hemoptysis, and hypoxemia
  • Lung CT: Halo of low attenuation surrounding a pulmonary nodule or a cavity.
  • Bronchoscopic examination demonstrates ulcerative or plaque-like lesions adherent to the tracheal wall
  • Isolation of Aspergillus spp. from respiratory secretions or the finding of septate hyphae consistent with Aspergillus spp. in respiratory samples in association with typical CT findings
Antifungal therapy is not recommended for prevention. Voriconazole 6 mg/kg IV q12h for 1 day, then 4 mg/kg IV q12h , followed by voriconazole PO 200 mg q12h after clinical improvement.
Table adapted from Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents [1]

Parasite

Disease Description Clinical Findings Diagnosis Prevention / Prophylaxis Treatment
Toxoplasma gondii Encephalitis

(Click here for more information)
  • Caused by the protozoan Toxoplasma gondii
  • The greatest risk of disease occurs among patients with a CD4+ <50 cells/µL
  • Primary infection occurs after eating undercooked meat containing tissue cysts or ingesting oocysts that have been shed in cat feces and have sporulated in the environment
Focal encephalitis with headache, confusion, or motor weakness and fever
  • Diagnosis is done with IgG antibodies.
  • CT scan or MRI of the brain will typically show multiple contrast-enhancing lesions, often with associated edema.
  • Definite diagnosis requires a brain biopsy.
  • PET is helpful to distinguish between toxoplasmosis and primary CNS lymphoma.
  • Start TMP-SMX prophylaxis when CD4+ <100 cells/µL
    Discontinue prophylaxis when CD4+ is >200 cells/µL for >3 month.
Administer:
Cryptosporidiosis

(Click here for more information)
  • Caused by the protozoan Cryptosporidium (C. hominis, C. parvum, and C. meleagridis)
  • The greatest risk of disease occurs among patients with a CD4+ <100 cells/µL
Acute or subacute onset of watery diarrhea, nausea, vomiting, lower abdominal pain. Fever is seen in 1/3 of patients. Microscopic examination of oocysts in stool with direct immunofluorescence.
  • Initiate ART
  • Education of possibles ways of transmission (infected patients, diapers, animals)
  • Avoid direct contact of pet stool
  • Scrupulous handwashing is recommended.
  • Initiate or optimize ART for immune restoration to CD4 count >100 cells/mm3
  • Aggressive oral and/or IV rehydration and replacement of electrolyte loss, and symptomatic treatment of diarrhea with anti- motility agent.
Microsporidiosis
  • The microsporidia reported as pathogens in humans include Encephalitozoon cuniculi, Encephalitozoon hellem, Encephalitozoon intestinalis, Enterocytozoon bieneusi, Trachipleistophora hominis, Trachipleistophora anthropophthera, Pleistophora species, P. ronneafiei, Vittaforma corneae, Microsporidium sp, Nosema ocularum, Anncaliia connori, Anncaliia vesicularum, and Anncaliia algerae.
  • The greatest risk of disease occurs among patients with a CD4+ <100 cells/µL

Clinical syndromes can vary by infecting species. The most common manifestation is diarrhea.

  • E. bieneusi is associated with malabsorption, diarrhea, and cholangitis.
  • E. cuniculi is associated with hepatitis, encephalitis, and disseminated disease.
  • E. intestinalis is associated with diarrhea, disseminated infection, and superficial keratoconjunctivitis.
  • E. hellem is associated with superficial keratoconjunctivitis, sinusitis, respiratory disease, prostatic abscesses, and disseminated infection.
  • Anncaliia and Trachipleistophora are associated with keratoconjunctivitis.
  • Nosema, Vittaforma, and Microsporidium are associated with stromal keratitis following trauma in immunocompetent hosts.
  • Pleistophora, Anncaliia, and Trachipleistophora are associated with myositis.
  • Trachipleistophora is associated with encephalitis and disseminated disease.
Examination of 3 stool samples with chromotrope and chemofluorescent stains
  • Patients who have CD4 counts <200 cells/µL should avoid untreated water sources.
  • No specific chemoprophylactic regimens are known to be effective in preventing microsporidiosis.
  • Initiate or optimize ART with immune restoration to CD4 count >100 cells/mm3
  • Severe dehydration, malnutrition, and wasting should be managed by fluid support and nutritional supplements
Table adapted from Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents [1]

Gallery

References

  1. 1.0 1.1 1.2 1.3 "Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Accessed Oct 2014" (PDF). line feed character in |title= at position 93 (help)
  2. 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 "Public Health Image Library (PHIL)".